DOCSLIB.ORG

TEDX the Endocrine Disruption Exchange 211 Grand Ave, Ste. 114, P.O

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TEDX the Endocrine Disruption Exchange 211 Grand Ave, Ste. 114, P.O TEDX The Endocrine Disruption Exchange 211 Grand Ave, Ste. 114, P.O. Box 1407, Paonia, CO 81428 970-527-4082 [email protected] References Acevedo HF, Tong JY, Hartsock RJ. 1995 . Human chorionic gonadotropin-beta subunit gene expression in cultured human fetal and cancer cells of different types and origins. Cancer 76:1467-1475. Abstract: BACKGROUND. The authors' previous investigations using living cultured human cancer cells and cells isolated from cancer tissues, analytical flow cytometry, and monoclonal antibodies directed to epitopes located in five different sites of the human chorionic gonadotropin (hCG) molecule, identified the presence of membrane-associated hCG, its subunits and fragments, by cells from all cancers, irrespective of type and origin, indicating that the expression of these sialoglycoproteins is a common phenotypic characteristic of cancer. Although benign neoplasms do not express these compounds, cultured human embryonic and fetal cells also express the same materials. To corroborate these findings, five fetal cell lines and 28 cancer cell lines were randomly selected from those previously studied, to determine the presence of translatable levels of hCG-beta (hCG beta) mRNA. METHODS. All cell lines were grown under identical conditions. Determination of hCG beta mRNA was made by extracting the total RNA from the cells, followed by synthesis of cDNA with RNase H- reverse transcriptase and polymerase chain reaction amplification using specific hCG beta-luteinizing hormone-beta (hLH beta) primers. The presence of amplified hCG beta cDNA was corroborated by hybridization of the product with an hCG beta-specific oligonucleotide and Southern blot analyses of the hybridization products. Gestational choriocarcinoma cells and HeLa adenocarcinoma of cervical cells, known producers of biologically active hCG, were positive control subjects, and human pituitary cells were used as negative control subjects. RESULTS. The results showed single and multiple hCG beta gene activation by the fetal cells and the different types of cancer, indicating that at any given time, there is the possibility of activation of as many as four genes of the six genes of the hCG beta-hLH beta gene cluster, even though alternative gene splicing cannot be ruled out. CONCLUSIONS. In addition to the authors' previous findings, the results of these studies support the concept that cancer is a problem of development and differentiation, and, to the authors' knowledge, prove definitively for the first time that synthesis and expression of hCG, its subunits, and its fragments, is a common biochemical denominator of cancer, providing the scientific basis for studies of its prevention and/or control by active and/or passive immunization against these sialoglycoproteins. Acharya S, Jayabose S, Kogan SJ, Tugal O, Beneck D, Leslie D, Slim M. 1997. Prenatally diagnosed neuroblastoma. Cancer 80:304-310. Abstract: BACKGROUND: Prenatally diagnosed neuroblastomas have been reported in increasing numbers over the past several years, and there are now a few reviews based on up to 21 cases. The purpose of this article is to review the clinical and biologic features of prenatally diagnosed neuroblastoma based on a review of 55 cases. METHODS: A review was conducted of 3 cases seen at the study institution and 52 other cases reported thus far in the literature. RESULTS: Prenatal diagnosis was made usually after 32 weeks of gestation. Approximately 93% of the tumors were adrenal in origin, and 44% of these were cystic. Thirty-seven patients (67%) had Stage I disease, 12 (22%) had Stage IV-S disease, and only 3 (5%) had Stage IV disease. The DNA index was favorable (> 1) in 14 of 16 patients studied. None of these 16 patients studied had amplification of the N-myc oncogene. Catecholamines were elevated in only 33% of the patients. The liver was the most common site of dissemination, which was observed in 25% of patients; bone involvement was not observed in any patient. Ultrasonography failed to detect existing hepatic metastasis in three patients. Primary surgical resection was performed in 47 patients (85%). Chemotherapy was given to five patients and radiotherapy to three. Of the 50 patients for whom follow-up information was available, 45 (90%) were alive at a range of 2-120 months from diagnosis. CONCLUSIONS: Prenatally diagnosed neuroblastomas are predominantly adrenal in origin and frequently cystic. The liver is the most common site of dissemination and bone involvement is notably absent. The vast majority of these infants have a favorable stage of disease (I, II, and IV-S) and favorable biologic features, and consequently have an excellent prognosis. Although surgery alone is curative for most patients, a period of observation may avoid surgery in some individuals who may achieve spontaneous regression. Adami HO, Persson I, Ekbom A, Wolk A, Ponten J, Trichopoulos D. 1995. The aetiology and pathogenesis of human breast cancer. Mutation Research-Fundamental & Molecular Mechanisms of Mutagenesis 333:29- 35. Abstract: Whilst investigators have clearly shown that non-hereditary factors dominate the aetiology of human breast cancer, they have failed to identify quantitatively important causes, and prospects for prevention remain indeed limited. However, progress in epidemiological and basic research has taken place during the last few years. Current evidence suggests that breast cancer may be affected by the intra-uterine environment, that exposures during adolescence are particularly important, and that pregnancy has a dual effect on breast cancer risk: an early increase followed by long-term protection. Great variation exists in the structural development of the breast ductal system already in the newborn - and by inference in utero - and a pregnancy induces permanent structural changes in the mammary gland. We suggest that these observations fit into an aetiological model with the following key components: (1) breast cancer risk depends on the number of cells at risk, the susceptibility of individual cells to malignant transformation, and on the degree of cellular proliferation, notably cells which can act as founders of breast cancer; (2) the number of target cells is determined by the hormonal environment mainly early in life, perhaps already in utero; (3) in adult life, hormones which are non-genotoxic, increase breast cancer risk by increasing selective cell proliferation and thus number of target cells and the risk of retention of spontaneous somatic mutations; (4) while a pregnancy stimulates the growth of already malignant cells or cells close to malignant transformation (and thereby entails a short-term risk increase) the dominating long-term protection occurs due to permanent structural changes, terminal differentiation and perhaps decreased cell proliferation and carcinogen-binding in combination. Adami J, Glimelius B, Cnattingius S, Ekbom A, Zahm SH, Linet M, Zack M. 1996. Maternal and perinatal factors associated with non-Hodgkin's lymphoma among children. Int J Cancer 65:774-777. Abstract: This nested case-control study based on 1.7 million live births in Sweden explores the associations between maternal and perinatal factors and the occurrence of childhood non-Hodgkin's lymphoma (NHL). The National Swedish Cancer Registry ascertained 168 cases in successive birth cohorts from 1973 through 1989 recorded in the Swedish Medical Birth Registry. From the nationwide Birth Registry, 5 controls without NHL and alive at the date the case was diagnosed were randomly selected from the pool of children, with each case matched by gender, birth year and birth month. Standardized information on selected maternal and perinatal factors up to one month after delivery were recorded in the Medical Birth Registry. Mothers of children with NHL were more likely than mothers of controls to have undergone Cesarean section [Odds ratio (OR) 1.6] and to have been exposed to paracervical anesthesia during delivery (OR 1.8). Children with NHL were more likely than controls to have endocrine-metabolic disorders (OR 3.3). This study is one of the largest focusing on the etiology of childhood NHL. Most of the maternal and perinatal characteristics studied did not markedly affect risk for childhood NHL, which may be due to maternal and perinatal factors not included in these data or to exposures later in life. (C) 1996 Wiley-Liss, Inc. Adey WR, Byus CV, Cain CD, Higgins RJ, Jones RA, Kean CJ, Kuster N, MacMurray A, Stagg RB, Zimmerman G, Phillips JL, Haggren W. 1999. Spontaneous and nitrosourea-induced primary tumors of the central nervous system in Fischer 344 rats chronically exposed to 836 MHz modulated microwaves. Radiat Res 152: 293-302. Abstract: We have tested an 836.55 MHz field with North American Digital Cellular (NADC) modulation in a 2-year animal bioassay that included fetal exposure. In offspring of pregnant Fischer 344 rats, we tested both spontaneous tumorigenicity and the incidence of induced central nervous system (CNS) tumors after a single dose of the carcinogen ethylnitrosourea (ENU) in utero, followed by intermittent digital- phone field exposure for 24 months. Far-field exposures began on gestational day 19 and continued until weaning at age 21 days. Near-field exposures began at 35 days and continued for the next 22 months, 4 consecutive days weekly, 2 h/day. SAR levels simulated localized peak brain exposures of a cell phone user. Of the 236 original rats, 182 (77%) survived to the termination of the whole experiment and were sacrificed at age 709-712 days. The 54 rats (23%) that died during the study ("preterm rats") formed a separate group for some statistical analyses. There was no evidence of tumorigenic effects in the CNS from exposure to the TDMA field. However, some evidence of tumor-inhibiting effects of TDMA exposure was apparent. Overall, the TDMA field-exposed animals exhibited trends toward a reduced incidence of spontaneous CNS tumors (P < 0. 16, two-tailed) and ENU-induced CNS tumors (P < 0.16, two-tailed). In preterm rats, where primary neural tumors were determined to be the cause of death, fields decreased the incidence of ENU-induced tumors (P < 0.03, two-tailed).
Load more

Recommended publications
  • Hull), 81 (Patrington), 89 (Brig) and 90 (Grimsby)
    Natural Environment Research Council INSTITUTE OF GEOLOGICAL SCIENCES Geological Survey of England and Wales Geological reports for DOE: Land use planning SOUTH HUMBERSIDE PROJECT Parts of TA ll,12 and 21 . included in 1:50 000 geological sheets 84) (Hull), 81 (Patrington), 89 (Brig) and 90 (Grimsby). I. T. Williamson BibliographicaZ reference Williamson, I. T. 1983. Geological reports for DOE: Land use planning. South Humberside Project. (Leeds Institute of Geological Sciences). Author I. T. Williamson Institute of Geological Sciences Ring Road Halton Leeds LS15 8TQ This report and the accompanying maps were commissioned and financed by the Department of the Environment The views expressed in this report are not necessarily those of the Department of the Environment c Crown copyright 1983 LEEDS INSTITUTE OF GEOLOGICAL SCIENCES 1983 Contents I Page PREFACE Chapter I INTRODUCTION 1 1 e? PhysiographyPopulation Distribution, Communications and Land Use i Chapter 2. GM)LOGY 3 2mlo SuperficialDeposits 3 Introduction 3 Made Ground or Fill 3 Tidal Flat and Saltings 4 Storm Gravel Beach Deposits 4 201 04. Peat 5 2.1.6~ Blown Sand 5 Alluvium 5 2rn1e8rn Marine or Estuarine Alluvium 6 Dry Valley Deposits 7 2.1.100 Head 7 2.1011. Till 8 2oIeI2e Sand and Gravel Deposits 9 Interglacial Deposits 11 2.1.14- The Kirmington Buried Channel 12 2.2. Bedrock ( 'Solid' Geology- 12 Structure 16 Chapter 3. GEOLOGICAL FACTORS AFFECTIXG THE SITISG OF LARGE SCALE DEVELOPMENT 17 3.1 0 ktroduction 17 3.2. Groundwater and Geomorphology 17 3.3. GeotechnicjlConsiderations 18 3.3.L Chalk 18 3.3.2, Sands and Gravels 19 3.3.3.
    [Show full text]
  • Failures and Controversies of the Antiestrogen Treatment of Breast Cancer
    In: Estrogen Prevention for Breast Cancer ISBN: 978-1-62417-378-3 Editor: Zsuzsanna Suba © 2013 Nova Science Publishers, Inc. No part of this digital document may be reproduced, stored in a retrieval system or transmitted commercially in any form or by any means. The publisher has taken reasonable care in the preparation of this digital document, but makes no expressed or implied warranty of any kind and assumes no responsibility for any errors or omissions. No liability is assumed for incidental or consequential damages in connection with or arising out of information contained herein. This digital document is sold with the clear understanding that the publisher is not engaged in rendering legal, medical or any other professional services. Chapter VII Failures and Controversies of the Antiestrogen Treatment of Breast Cancer Zsuzsanna Suba National Institute of Oncology, Department of Surgical and Molecular Pathology, Budapest, Hungary Abstract In postmenopausal women, estrogens have unquestionable preventive and curative effects against atherogenic cardiovascular lesions, osteoporosis and neurodegenerative diseases. Moreover, recent studies on correlations between hormone replacement therapy and cancer risk could justify preventive, anticancer capacities of estrogen both on smoking associated and hormone related cancers. Experimental developing of antiestrogen compounds aimed to inhibit the binding of presumably harmful, endogenous estrogen to its receptor system so as to achieve a regression of hormone-related cancers. However, antiestrogens proved to be ineffective in the majority of selected receptor positive breast cancer cases and produced severe side effects, such as vascular complications and cancer development at several sites. Failure of antiestrogen therapy was designated as ―endocrine resistance‖ of tumors.
    [Show full text]
  • Exposure to Female Hormone Drugs During Pregnancy
    British Journal of Cancer (1999) 80(7), 1092–1097 © 1999 Cancer Research Campaign Article no. bjoc.1998.0469 Exposure to female hormone drugs during pregnancy: effect on malformations and cancer E Hemminki, M Gissler and H Toukomaa National Research and Development Centre for Welfare and Health, Health Services Research Unit, PO Box 220, 00531 Helsinki, Finland Summary This study aimed to investigate whether the use of female sex hormone drugs during pregnancy is a risk factor for subsequent breast and other oestrogen-dependent cancers among mothers and their children and for genital malformations in the children. A retrospective cohort of 2052 hormone-drug exposed mothers, 2038 control mothers and their 4130 infants was collected from maternity centres in Helsinki from 1954 to 1963. Cancer cases were searched for in national registers through record linkage. Exposures were examined by the type of the drug (oestrogen, progestin only) and by timing (early in pregnancy, only late in pregnancy). There were no statistically significant differences between the groups with regard to mothers’ cancer, either in total or in specified hormone-dependent cancers. The total number of malformations recorded, as well as malformations of the genitals in male infants, were higher among exposed children. The number of cancers among the offspring was small and none of the differences between groups were statistically significant. The study supports the hypothesis that oestrogen or progestin drug therapy during pregnancy causes malformations among children who were exposed in utero but does not support the hypothesis that it causes cancer later in life in the mother; the power to study cancers in offspring, however, was very low.
    [Show full text]
  • NDA/BLA Multi-Disciplinary Review and Evaluation
    NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) NDA/BLA Multi-Disciplinary Review and Evaluation Application Type NDA Application Number(s) NDA 214154 (IND 110682) Priority or Standard Standard Submit Date(s) April 15, 2020 Received Date(s) April 15, 2020 PDUFA Goal Date April 15, 2021 Division/Office Division of Urology, Obstetrics, and Gynecology (DUOG) / Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine (ORPURM) Review Completion Date April 15, 2021 Established/Proper Name drospirenone and estetrol tablets (Proposed) Trade Name Nextstellis Pharmacologic Class Combination hormonal contraceptive Applicant Mayne Pharma LLC Dosage form Tablet Applicant proposed Dosing x Take one tablet by mouth at the same time every day. Regimen x Take tablets in the order directed on the blister pack. Applicant Proposed For use by females of reproductive potential to prevent Indication(s)/Population(s) pregnancy Recommendation on Approval Regulatory Action Recommended For use by females of reproductive potential to prevent Indication(s)/Population(s) pregnancy (if applicable) Recommended Dosing x Take one pink tablet (drospirenone 3 mg, estetrol Regimen anhydrous 14.2 mg) by mouth at the same time every day for 24 days x Take one white inert tablet (placebo) by mouth at the same time every day for 4 days following the pink tablets x Take tablets in the order directed on the blister pack 1 Reference ID: 4778993 NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) Table of Contents Table of Tables .................................................................................................................... 5 Table of Figures ................................................................................................................... 7 Reviewers of Multi-Disciplinary Review and Evaluation ...................................................
    [Show full text]
  • Local Government Boundary Commission for England
    If LOCAL GOVERNMENT BOUNDARY COMMISSION FOR ENGLAND REVIEW OF NON-METROPOLITAN COUNTIES FURTHER REVIEW OF THE COUNTY OF HUMBERSIDE NORTH YORKSHIRE EAST YORKSHIRE HUMBERSIDE EAST YORKSHIRE _J \\HOLDERNESS BOROUGH OF BEVERLEY ^KINGSTON UPON HU SOUTH YORKSHIRE LINCOLNSHIRE REPORT NO. 604 I I I I I I I • LOCAL GOVERNMENT I BOUNDARY COMMISSION I FOR ENGLAND iI REPORT NO. 604 i i i i i i i i i I I I • LOCAL GOVERNMENT BOUNDARY COMMISSION FOR ENGLAND I I CHAIRMAN MR G J ELLERTON I MEMBERS MR K F J ENNALS MR G R PRENTICE I MRS H R V SARKANY I MR C W SMITH I PROFESSOR K YOUNG I I I I I I I I I I I CONTENTS The Making of Numberside The Progress of the Humberside Reviews 2.1 The Commission's Initial Review i 2.2 The Secretary of State's Direction 2.3 The Commission's Further Review 2.4 The Commission's Interim Decision 2.5 The Commission's Draft Proposal i 2.6 The Response to the Commission's Draft Proposal i The Commission's Approach to the Further Review and its Consideration of the Case For and Against Change i 3.1 The Criteria for Boundary Changes 3.2 The Wishes of the People 3.3 The Pattern of Community Life 3.4 The Effective Operation of Local Government and i Associated Services i The Commission's Conclusions and Final Proposal 4.1 The Commission's Conclusions 4.2 The Commission's Final Proposal i 4.3 Electoral Consequences 4.4 Second Order Boundary Issues 4.5 Unitary Authorities i 4.6 Publication i i Annexes 1.
    [Show full text]
  • INTERNAL POST Members Information INTERNAL POST
    HUMBER BRIDGE Councillor L Redfern Councillor D Gemmell BOARD North Lincolnshire Council, Civic Kingston upon Hull City Council Centre Ashby Road Scunthorpe DN16 1AN Councillor S Parnaby OBE, Councillor C Shaw Lord C Haskins East Riding of Yorkshire Council North East Lincolnshire Council Quarryside Farm, County Hall Skidby, Beverley Cottingham, HU17 9BA East Yorkshire, HU16 5TG Mr S Martin Professor D Stephenson Mr J Butler Chief Executive, Clugston Clerk to the Humber Bridge 33 Hambling Drive Group Ltd Board Molescroft St Vincent House, Normanby Beverley Road, Scunthorpe HU17 9GD DN15 8QT Mr P Hill Mr P Dearing Anita Eckersley General Manager and Legal Services Committee Clerk to the Humber Bridgemaster Kingston upon Hull City Council Bridge Board Humber Bridge Administration Offices Ferriby Road, Hessle HU13 0JG Councillor Turner MBE, Other recipients for Mrs J Rae, Audit Commission Lincolnshire County Council information, Audit Commission c/o Hull City Council, Floor 2 Wilson Centre, Alfred Gelder Street, Hull HU1 2AG Nigel Pearson Simon Driver Shaun Walsh, Chief Executive Chief Executive Chief Executive East riding of Yorkshire Council North Lincolnshire Council North East Lincolnshire Council Civic Centre, Ashby Road Municipal Offices, Town Hall Scunthorpe Square, Grimsby DN16 1AN DN31 1HU INTERNAL POST INTERNAL POST Members Information Reference Library APPEALS COMMITTEE Councillor Abbott Councillor Conner Councillor P D Clark INTERNAL MAIL INTERNAL MAIL G Paddock K Bowen Neighbourhood Nuisance Team Neighbourhood Nuisance Team HAND
    [Show full text]
  • Effects of Diethylstilbestrol, Norethindrone, and Mestranol on Selected Microbes
    Loyola University Chicago Loyola eCommons Master's Theses Theses and Dissertations 1974 Effects of Diethylstilbestrol, Norethindrone, and Mestranol on Selected Microbes John N. Haan Loyola University Chicago Follow this and additional works at: https://ecommons.luc.edu/luc_theses Part of the Physiology Commons Recommended Citation Haan, John N., "Effects of Diethylstilbestrol, Norethindrone, and Mestranol on Selected Microbes" (1974). Master's Theses. 2756. https://ecommons.luc.edu/luc_theses/2756 This Thesis is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It has been accepted for inclusion in Master's Theses by an authorized administrator of Loyola eCommons. For more information, please contact [email protected]. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. Copyright © 1974 John N. Haan EFFECTS OF DIETHYLSTILBESTROL, NORETHINDRONE, AND MESTRANOL ON SELECTED MICROBES by John N. Haan A Thesis Submitted to the Faculty of the Graduate School of Loyola University of Chicago in Partial Fulfillment of the Requirements for the Degree of Master of Science November 1974 TABLE OF CONTENTS ,.' I. Introduction and Review of the Literature ................... 1 'II. Materials and Methods....................................... 7 III. Results· ..................................................... 13 A. Effects of Ethanol on the Microbes Studied .............. 13 1. Growth Studies ...................................... 13 B. Effects of Norethindrone
    [Show full text]
  • Studies on Squamous Metaplasia in Rat Bladder II . Effects of Estradiol and Estradiol Plus Hexestrol*T
    Studies on Squamous Metaplasia in Rat Bladder II . Effects of Estradiol and Estradiol plus Hexestrol*t A. ANGRIST, P. CAPURRO, AND B. MOUMGIS (Department of Pathology, Albert Einstein College of Medicine of Yeshiva University, New York 61, N.Y.) SUMMARY The effects of estrogens were studied with and without foreign body (rough glass beads and paraffin pellets) on the metaplasia of the bladder of rats on stock main tenance diet and on a vitamin A-deficient diet. Estradiol increased the degree of metaplasia in the bladder of rats when combined with vitamin A deficiency and/or foreign body stimulation. Estradiol affected bladder epithelium already made squamous more effectively than it did the normal transitional uroepithelium. A high dose of hexestrol, when added to estradiol, showed no enhance ment of the degree of metaplasi.a by estradiol benzoate in the bladder of the rat. The combination of vitamin A deficiency, foreign body in situ, and estrogenadminis tration was an effective means of obtaining keratinizing squamous metaplasia in the urinary bladder for studies of its developmental and reversal changes. In a previous presentation (4) the relation of The animals were divided into the following different forms of foreign-body irritation and of groups (the number of rats surviving with tissue vitamin A deficiency to squamous metaplasia in for study and the total number in each group mi the bladders of rats was reported. It is also known tinily are given following each group): that estrogens will cause squamous metaplasia. I. Stock diet + estradiol (6 survivals/lI rats) The metaplasia following estrogen administration II.
    [Show full text]
  • A Phosphotyrosyl Peptide That Blocks Dimerization of the Human Estrogen Receptor (Estradiol/MCF-7 Cells/Tyrosine Phosphorylation/Dimerization/DNA Binding) STEVEN F
    Proc. Natl. Acad. Sci. USA Vol. 92, pp. 7475-7479, August 1995 Biochemistry An antiestrogen: A phosphotyrosyl peptide that blocks dimerization of the human estrogen receptor (estradiol/MCF-7 cells/tyrosine phosphorylation/dimerization/DNA binding) STEVEN F. ARNOLD AND ANGELO C. NOTIDES* Departments of Environmental Medicine and Biophysics, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642 Communicated by Jack Gorski, University of Wisconsin, Madison, WI, April 28, 1995 (received for review January 13, 1995) ABSTRACT We have previously identified tyrosine-537 scription (STAT) bind DNA as dimers through a reciprocal as a constitutively phosphorylated site on the human estrogen association of a phosphotyrosine on one monomer with a Src receptor (hER). A 12-amino acid phosphotyrosyl peptide homology 2 domain (SH2 domain) on the complementary containing a selected sequence surrounding tyrosine-537 was monomer (15, 16). used to investigate the function of phosphotyrosine-537. The Deletion and mutational analyses have provided evidence phosphotyrosyl peptide completely blocked the binding of the that the C terminus of the steroid hormone receptors is hER to an estrogen response element (ERE) in a gel mobility necessary for receptor dimerization (4). The dimerization of shift assay. Neither the nonphosphorylated tyrosyl peptide the nuclear hormone receptors is reported to be regulated by nor an unrelated phosphotyrosyl peptide previously shown to hydrophobic heptad repeats in the C terminus (17, 18). A inhibit the signal transducers and activators of transcription 22-amino acid sequence from positions 501 to 522 in the C factor (STAT) blocked binding of the hER to the ERE. The terminus of the mouse estrogen receptor was isolated that hER phosphotyrosyl peptide was shown by molecular sizing conferred DNA binding to DNA-binding-deficient mutants chromatography to dissociate the hER dimer into monomers.
    [Show full text]
  • Diethylstilbestrol Lignant Cervical and Vaginal Tumors (Polyps, Squamous-Cell Papilloma, and Myosarcoma) in Female Hamsters, and Benign and Malignant Tes­ CAS No
    Report on Carcinogens, Fourteenth Edition For Table of Contents, see home page: http://ntp.niehs.nih.gov/go/roc Diethylstilbestrol lignant cervical and vaginal tumors (polyps, squamous­cell papilloma, and myosarcoma) in female hamsters, and benign and malignant tes­ CAS No. 56-53-1 ticular tumors (granuloma, adenoma, and leiomyosarcoma) in male hamsters. Prenatal exposure also caused uterine cancer (adenocarci­ Known to be a human carcinogen noma) in female mice and hamsters, benign ovarian tumors (cystad­ First listed in the First Annual Report on Carcinogens (1980) enoma and granulosa­cell tumors) in female mice, and benign lung Also known as DES, diethylstilboestrol, or stilboestrol tumors (papillary adenoma) in mice of both sexes. Prenatal expo­ sure did not cause tumors in monkeys observed for up to six years CH 3 after birth. Mice developed cervical and vaginal tumors after receiv­ H2C ing a single subcutaneous injection of diethylstilbestrol on the first C OH day of life, and male rats developed cancer of the reproductive tract HO C (squamous­cell carcinoma) after receiving daily subcutaneous injec­ CH2 tions for the first month of life. Diethylstilbestrol also caused cancer in experimental animals ex­ H3C Carcinogenicity posed as adults. When administered orally, diethylstilbestrol caused cancer of the mammary gland (carcinoma and adenocarcinoma) in Diethylstilbestrol is known to be a human carcinogen based on suffi­ mice of both sexes and benign mammary­gland tumors (fibroade­ cient evidence of carcinogenicity from studies in humans. noma) in rats of both sexes. In addition, cancer of the cervix and uterus (adenocarcinoma), vagina (squamous­cell carcinoma), and Cancer Studies in Humans bone (osteosarcoma) occurred in mice, and benign and malignant The strongest evidence for carcinogenicity comes from epidemiolog­ pituitary­gland and liver tumors (hepatocellular tumors and heman­ ical studies of women exposed to diethylstilbestrol in utero (“diethyl­ gioendothelioma) occurred in rats.
    [Show full text]
  • Humber Local Pharmaceutical Committee Representing Pharmacy Contractors in East Riding of Yorkshire, Hull and North & North East Lincolnshire
    Humber Local Pharmaceutical Committee Representing Pharmacy Contractors in East Riding of Yorkshire, Hull and North & North East Lincolnshire Open/Closed/Strategy Meeting Wednesday 3 January 2018 Held at Cottingham Parks Golf Club, Cottingham This meeting was conducted in line with the LPC Code of Conduct and Accountability Present: Paul Robinson – Chair Employed Chair PR Joanne Lane – Vice Chair Independent representative JL Karen Bednarski CCA representative KB Manish Khanna Independent representative MK Annette Maudar CCA representative AF David Miller CCA representative DM Karen Murden CCA representative/Pharmacy Contract Support Lead KM Ian Woolley Independent representative IW Matthew Greenwood CCA representative MG David Broome PSNC representative DB Anthony Bryce Health Integration Lead AB Joanne Carter LPC Office Manager JDC Janet M Clark LPC Chief Officer JMC Steve Mosley SIP SM Kate Knapik Observer – Whitworths Chemist KK Apologies: Caroline Hayward PDP CJH John Mackenzie Independent representative JEM Lisa McGowan CCA representative LM Fiona Sitch AIMp representative FS Kate Stark LPC Admin Officer KS Jon Whitelam CCA representative JW Did not attend: Dana Field CCA representative DF The meeting commenced at 9.30am. Action 1. Apologies for absence and introductions: Apologies as above. 2. Committee Governance: 2.1 i. Members to note the contents of the LPC Code of Conduct & inform the Chair of any changes to their declarations of interests ii. Competition Law Compliance Guidelines Noted by all members 3. Minutes of the last meeting – 6.9.17: Humber LPC minutes: Minutes of the last LPC meeting had been circulated prior to the meeting and were accepted as a true record with some spelling amendments.
    [Show full text]
  • Use of Aromatase Inhibitors in Breast Carcinoma
    Endocrine-Related Cancer (1999) 6 75-92 Use of aromatase inhibitors in breast carcinoma R J Santen and H A Harvey1 Department of Medicine, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA 1Department of Medicine, Penn State College of Medicine, Hershey, Pennsylvania 17033, USA (Requests for offprints should be addressed to R J Santen) Abstract Aromatase, a cytochrome P-450 enzyme that catalyzes the conversion of androgens to estrogens, is the major mechanism of estrogen synthesis in the post-menopausal woman. We review some of the recent scientific advances which shed light on the biologic significance, physiology, expression and regulation of aromatase in breast tissue. Inhibition of aromatase, the terminal step in estrogen biosynthesis, provides a way of treating hormone-dependent breast cancer in older patients. Aminoglutethimide was the first widely used aromatase inhibitor but had several clinical drawbacks. Newer agents are considerably more selective, more potent, less toxic and easier to use in the clinical setting. This article reviews the clinical data supporting the use of the potent, oral competitive aromatase inhibitors anastrozole, letrozole and vorozole and the irreversible inhibitors 4-OH andro- stenedione and exemestane. The more potent compounds inhibit both peripheral and intra-tumoral aromatase. We discuss the evidence supporting the notion that aromatase inhibitors lack cross- resistance with antiestrogens and suggest that the newer, more potent compounds may have a particular application in breast cancer treatment in a setting of adaptive hypersensitivity to estrogens. Currently available aromatase inhibitors are safe and effective in the management of hormone- dependent breast cancer in post-menopausal women failing antiestrogen therapy and should now be used before progestational agents.
    [Show full text]